A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Terminated

Phase 3 Results N/A

Eligibility Criteria

Inclusion Criteria

- Patients with diagnosis of acute ischemic stroke with onset within 5 hours and 30 minutes before randomization and planned treatment initiation within 6 hours of onset
- After 600 patients are enrolled in previous criteria, the new criteria for enrollment will be, patients with diagnosis of acute ischemic stroke with onset within 4 hours and 30 minutes before randomization and planned treatment initiation within 5 hours of onset

Exclusion Criteria

- Patients who had participation in another study with an investigational drug or device within the last 30 days, prior participation in the present study, or planned participation in another trial
- Patients with symptoms suggestive of subarachnoid hemorrhage
- Female patients known to be pregnant, lactating, or having a positive or indeterminate pregnancy test
- Patients with neurological deficit that has led to stupor or coma
- Patients with minor stroke